Novartis is in Chicago for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and has brought along an interactive experience for the weekend. The Swiss drugmaker is rolling out its ...

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

The immediate goal of Chronic Myeloid Leukemia (CML) therapy, operational cure, is defined as survival like sex- age-adjusted normals and a normal quality-of-life (QoL). This is being met in many ...

Lindsay A. Rein, MD, reviews exciting data presented at this year’s ASH meeting, focusing on chronic myeloid leukemia (CML) and the recent approval of asciminib, a novel agent for first-, second-, and ...

Medications for CML directly destroy cancer cells or help the body’s immune system attack cancer cells to prevent them from growing. Medications may not cure CML, so people may need to continue taking ...

A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...

When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, generic imatinib ...

Most — though not all — side effects from chronic myeloid leukemia treatment improve over time, an expert said. Most side effects from chronic myeloid leukemia (CML) treatment are manageable and will ...